Application of circulating tumor DNA in targeted therapy and immunotherapy of metastatic melanoma / 国际肿瘤学杂志

Targeted therapy and immunotherapy are important methods for the treatment of metastatic melanoma, but monitoring the patient′s disease progress and treatment response during the treatment is the key to accurate treatment and personalized treatment.Circulating tumor DNA (ctDNA) as a non-invasive " liquid biopsy" method, due to its high sensitivity and specificity for gene mutations, and the advantages of being qualitative, quantitative and traceable, which has shown great application value in monitoring metastatic melanoma progression, evaluating efficacy, and predicting prognosis during targeted therapy and immuno-therapy.

Research and application of PD-1 / PD-L1 inhibitors in small cell lung cancer / 国际肿瘤学杂志

Small cell lung cancer (SCLC)is an aggressive neuroendocrine carcinoma with a very high degree of malignancy. Currently,the standard treatment for SCLC is still chemoradiotherapy,and although SCLC is sensitive to chemotherapy in the early stage,recurrence and metastasis often occur due to drug resis-tance. In recent years,immunotherapy has made some progress in the study of SCLC. The immunodetection point programmed death-1 (PD-1)and its ligand (PD-L1)inhibitors,such as nivolumab,atezolizumab and pabolizumab,have shown good antitumor activity in clinical studies of SCLC,and PD-1 / PD-L1 inhibitors com-bined with chemotherapy have shown better efficacy,providing a new strategy for the treatment of SCLC.

Research and application of PD-1/PD-L1 inhibitors in small cell lung cancer / 国际肿瘤学杂志

Small cell lung cancer (SCLC) is an aggressive neuroendocrine carcinoma with a very high degree of malignancy. Currently, the standard treatment for SCLC is still chemoradiotherapy, and although SCLC is sensitive to chemotherapy in the early stage, recurrence and metastasis often occur due to drug resis-tance. In recent years, immunotherapy has made some progress in the study of SCLC. The immunodetection point programmed death-1 (PD-1) and its ligand (PD-L1) inhibitors, such as nivolumab, atezolizumab and pabolizumab, have shown good antitumor activity in clinical studies of SCLC, and PD-1/PD-L1 inhibitors combined with chemotherapy have shown better efficacy, providing a new strategy for the treatment of SCLC.